314 related articles for article (PubMed ID: 27283871)
1. Restoring regulation - IL-2 therapy in systemic lupus erythematosus.
Humrich JY; Riemekasten G
Expert Rev Clin Immunol; 2016 Nov; 12(11):1153-1160. PubMed ID: 27283871
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cells in systemic lupus erythematosus.
Ohl K; Tenbrock K
Eur J Immunol; 2015 Feb; 45(2):344-55. PubMed ID: 25378177
[TBL] [Abstract][Full Text] [Related]
3. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus.
Humrich JY; Riemekasten G
Curr Opin Rheumatol; 2019 Mar; 31(2):208-212. PubMed ID: 30562181
[TBL] [Abstract][Full Text] [Related]
4. Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus.
Mizui M; Tsokos GC
Front Immunol; 2018; 9():786. PubMed ID: 29755456
[TBL] [Abstract][Full Text] [Related]
5. Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus.
Akbarzadeh R; Riemekasten G; Humrich JY
Curr Opin Rheumatol; 2023 Mar; 35(2):98-106. PubMed ID: 36563007
[TBL] [Abstract][Full Text] [Related]
6. [Regulatory T-cells in systemic lupus erythematosus. IL-2 is decisive for loss of tolerance].
Ohl K; Tenbrock K
Z Rheumatol; 2016 Apr; 75(3):253-64. PubMed ID: 26975190
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T Cells in SLE: Biology and Use in Treatment.
Giang S; La Cava A
Curr Rheumatol Rep; 2016 Nov; 18(11):67. PubMed ID: 27704250
[TBL] [Abstract][Full Text] [Related]
8. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.
von Spee-Mayer C; Siegert E; Abdirama D; Rose A; Klaus A; Alexander T; Enghard P; Sawitzki B; Hiepe F; Radbruch A; Burmester GR; Riemekasten G; Humrich JY
Ann Rheum Dis; 2016 Jul; 75(7):1407-15. PubMed ID: 26324847
[TBL] [Abstract][Full Text] [Related]
9. Low-Dose IL-2 in the Treatment of Lupus.
Mizui M; Tsokos GC
Curr Rheumatol Rep; 2016 Nov; 18(11):68. PubMed ID: 27734211
[TBL] [Abstract][Full Text] [Related]
10. [IL-2-Therapy in SLE- Selective reconstitution of immunological tolerance].
Humrich JY; Riemekasten G
Z Rheumatol; 2016 Jun; 75(5):490-2. PubMed ID: 27250490
[No Abstract] [Full Text] [Related]
11. Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp
Ferreira RC; Castro Dopico X; Oliveira JJ; Rainbow DB; Yang JH; Trzupek D; Todd SA; McNeill M; Steri M; Orrù V; Fiorillo E; Crouch DJM; Pekalski ML; Cucca F; Tree TI; Vyse TJ; Wicker LS; Todd JA
Front Immunol; 2019; 10():2606. PubMed ID: 31781109
[TBL] [Abstract][Full Text] [Related]
12. Expansion of regulatory T cells using low-dose interleukin-2 attenuates hypertension in an experimental model of systemic lupus erythematosus.
Taylor EB; Sasser JM; Maeda KJ; Ryan MJ
Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1274-F1284. PubMed ID: 30892934
[TBL] [Abstract][Full Text] [Related]
13. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells.
Scheinecker C; Bonelli M; Smolen JS
J Autoimmun; 2010 Nov; 35(3):269-75. PubMed ID: 20638240
[TBL] [Abstract][Full Text] [Related]
14. Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus.
Alexander T; Sattler A; Templin L; Kohler S; Groß C; Meisel A; Sawitzki B; Burmester GR; Arnold R; Radbruch A; Thiel A; Hiepe F
Ann Rheum Dis; 2013 Sep; 72(9):1549-58. PubMed ID: 23264341
[TBL] [Abstract][Full Text] [Related]
15. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus.
Robinson S; Thomas R
Front Immunol; 2021; 12():654701. PubMed ID: 34335564
[TBL] [Abstract][Full Text] [Related]
16. IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4+ T Cells in Murine Lupus Nephritis.
Rose A; von Spee-Mayer C; Kloke L; Wu K; Kühl A; Enghard P; Burmester GR; Riemekasten G; Humrich JY
Cells; 2019 Oct; 8(10):. PubMed ID: 31614462
[TBL] [Abstract][Full Text] [Related]
17. Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus.
Venigalla RK; Tretter T; Krienke S; Max R; Eckstein V; Blank N; Fiehn C; Ho AD; Lorenz HM
Arthritis Rheum; 2008 Jul; 58(7):2120-30. PubMed ID: 18576316
[TBL] [Abstract][Full Text] [Related]
18. CD(+)(4)CD(+)(25) Treg cells in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus patients.
Huang H; Sun W; Liang Y; Long XD; Peng Y; Liu Z; Wen X; Jia M
Ren Fail; 2014 Sep; 36(8):1263-7. PubMed ID: 24990576
[TBL] [Abstract][Full Text] [Related]
19. [Interleukin-2 signaling pathway regulating molecules in systemic lupus erythematosus].
Guo Q; Chen XY; Su Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):1100-1104. PubMed ID: 27987522
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T cells in systemic lupus erythematosus (SLE); role of peptide tolerance.
Sawla P; Hossain A; Hahn BH; Singh RP
Autoimmun Rev; 2012 Jul; 11(9):611-4. PubMed ID: 22001419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
